CR20160030A - Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen - Google Patents
Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienenInfo
- Publication number
- CR20160030A CR20160030A CR20160030A CR20160030A CR20160030A CR 20160030 A CR20160030 A CR 20160030A CR 20160030 A CR20160030 A CR 20160030A CR 20160030 A CR20160030 A CR 20160030A CR 20160030 A CR20160030 A CR 20160030A
- Authority
- CR
- Costa Rica
- Prior art keywords
- preparation
- pharmaceutical compositions
- compositions containing
- isoquinoline compounds
- new isoindoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Abstract
Compuestos de fórmula (I): en la que Het, R3, R4, R5, R7, R8, R9, T, p, p', q, y q' son como se han definido en la descripción
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1357276A FR3008977A1 (fr) | 2013-07-23 | 2013-07-23 | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| PCT/EP2014/065764 WO2015011164A1 (en) | 2013-07-23 | 2014-07-22 | New isoindoline or isoquinoline compounds, a process for their preparation and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20160030A true CR20160030A (es) | 2016-03-09 |
Family
ID=49911606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20160030A CR20160030A (es) | 2013-07-23 | 2016-01-15 | Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen |
Country Status (49)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3008977A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP3445762B1 (en) | 2016-04-20 | 2023-09-13 | Bristol-Myers Squibb Company | Substituted bicyclic heterocyclic compounds |
| WO2020006296A1 (en) | 2018-06-27 | 2020-01-02 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| CN114728926A (zh) * | 2019-11-15 | 2022-07-08 | 武汉朗来科技发展有限公司 | 一种rock抑制剂及其制备方法和用途 |
| CN112010796B (zh) * | 2020-09-17 | 2022-04-22 | 浙江大学 | 光学活性3-(1,1-二氟-2-氧-2-芳基乙基)异吲哚啉-1-酮衍生物制备方法 |
| US12245355B2 (en) | 2021-02-19 | 2025-03-04 | Mevion Medical Systems, Inc. | Gantry for a particle therapy system |
| KR20230160303A (ko) * | 2021-03-24 | 2023-11-23 | 르 라보레또레 쎄르비에르 | ５－｛５－클로로－２－[(3s)－３－[(모르폴린－４－일)메틸]－３,４－디하이드로이소퀴놀린－２(１ｈ)－카르보닐]페닐｝－１,２－디메틸－１ｈ－피롤－３－카르복실산 유도체의 신규한 합성 방법 및 약학적 화합물의 생산을 위한 이의 용도 |
| AR128587A1 (es) | 2022-02-24 | 2024-05-22 | Servier Lab | Derivados de 5-[7-(3,4-dihidro-1h-isoquinolina-2-carbonil)-1,2,3,4-tetrahidroisoquinolin-6-il]-1h-pirrol-3-carboxamida, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos |
| IL317101A (en) | 2022-05-20 | 2025-01-01 | Novartis Ag | Antibody-drug conjugates of anticancer compounds and methods of using them |
| US20260098022A1 (en) * | 2023-03-31 | 2026-04-09 | Mitsui Chemicals, Inc. | Carbamate compound |
| AR134424A1 (es) | 2023-11-22 | 2026-01-14 | Novartis Ag | Conjugados de anticuerpo anti-cd7-fármaco y métodos de uso de los mismos |
| UY40985A (es) | 2023-11-22 | 2025-06-30 | Servier Lab | Conjugados de anticuerpo anti-cd74-fármaco y métodos de uso de los mismos |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003234464B2 (en) | 2002-05-03 | 2009-06-04 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| WO2004096774A1 (en) * | 2003-05-01 | 2004-11-11 | Glaxo Group Limited | Acyl isoindoline derivatives and acyl isoquinoline derivatives as anti-viral agents |
| US20050070570A1 (en) | 2003-06-18 | 2005-03-31 | 4Sc Ag | Novel potassium channels modulators |
| BRPI0514504A (pt) * | 2004-08-20 | 2008-06-10 | Univ Michigan | pequenas moléculas inibidoras de membros da famìlia bcl-2 anti-apoptóticos e os usos das mesmas |
| CN101039662A (zh) * | 2004-08-20 | 2007-09-19 | 密执安州立大学董事会 | 抗－细胞凋亡bcl－2家族成员的小分子抑制剂及其应用 |
| US20080227792A1 (en) * | 2005-02-15 | 2008-09-18 | Novo Nordisk A/S | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters |
| KR101511074B1 (ko) | 2007-04-16 | 2015-04-13 | 애브비 인코포레이티드 | 7-치환된 인돌 Ｍｃｌ-1 억제제 |
| CN102007101A (zh) | 2007-11-30 | 2011-04-06 | 生物区科学管理控股有限公司 | 作为抗菌剂的四氢-异喹啉ppat抑制剂 |
| JP5496915B2 (ja) | 2008-02-13 | 2014-05-21 | シージーアイ ファーマシューティカルズ，インコーポレーテッド | ６−アリール−イミダゾ［１，２−ａ］ピラジン誘導体、その製造方法、及びその使用方法 |
| WO2009102463A2 (en) | 2008-02-14 | 2009-08-20 | Connor Reynolds | Pet waste vacuum system and apparatus, disposable liners therefor, and a method of collecting pet waste using same |
| CN103732589B (zh) * | 2011-05-25 | 2016-03-30 | 百时美施贵宝公司 | 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺 |
| AU2012355623A1 (en) * | 2011-12-23 | 2014-07-17 | Novartis Ag | Compounds for inhibiting the interaction of BCL2 with binding partners |
| EP2798432A4 (en) | 2011-12-27 | 2015-07-22 | Intel Corp | METHODS AND SYSTEMS FOR CONTROLLING POWER SUPPLY NETWORKS DURING AN ACTIVE STATE OF A PERIODICALLY TRIGGERED DOMAIN IN ACCORDANCE WITH PERIODICALLY RELEASED DOMAIN LOADING CONDITIONS |
| FR2986002B1 (fr) * | 2012-01-24 | 2014-02-21 | Servier Lab | Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008977A1 (fr) * | 2013-07-23 | 2015-01-30 | Servier Lab | Nouveaux derives d'isoindoline ou d'isoquinoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR3008979B1 (fr) * | 2013-07-23 | 2015-07-24 | Servier Lab | Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2013
- 2013-07-23 FR FR1357276A patent/FR3008977A1/fr not_active Withdrawn
-
2014
- 2014-07-13 JO JOP/2014/0223A patent/JO3457B1/ar active
- 2014-07-15 UY UY0001035664A patent/UY35664A/es active IP Right Grant
- 2014-07-22 CN CN201811358313.9A patent/CN109456324B/zh active Active
- 2014-07-22 GE GEAP201414063A patent/GEP20207070B/en unknown
- 2014-07-22 AU AU2014295101A patent/AU2014295101B2/en active Active
- 2014-07-22 HU HUE14741648A patent/HUE041443T2/hu unknown
- 2014-07-22 CN CN201480042422.3A patent/CN105431422B/zh active Active
- 2014-07-22 BR BR112016001080-9A patent/BR112016001080B1/pt active IP Right Grant
- 2014-07-22 CU CUP2016000010A patent/CU24352B1/es unknown
- 2014-07-22 HR HRP20190277TT patent/HRP20190277T1/hr unknown
- 2014-07-22 JP JP2016528512A patent/JP6395829B2/ja active Active
- 2014-07-22 EP EP14741648.1A patent/EP3024826B1/en active Active
- 2014-07-22 ES ES14741648T patent/ES2711371T3/es active Active
- 2014-07-22 TN TN2016000003A patent/TN2016000003A1/en unknown
- 2014-07-22 EA EA201600122A patent/EA032301B1/ru unknown
- 2014-07-22 MX MX2016000904A patent/MX365373B/es active IP Right Grant
- 2014-07-22 WO PCT/EP2014/065764 patent/WO2015011164A1/en not_active Ceased
- 2014-07-22 KR KR1020167004570A patent/KR102008431B1/ko active Active
- 2014-07-22 ME MEP-2019-35A patent/ME03346B/me unknown
- 2014-07-22 NZ NZ716155A patent/NZ716155A/en unknown
- 2014-07-22 MD MDA20160018A patent/MD4793C1/ro not_active IP Right Cessation
- 2014-07-22 TW TW103125161A patent/TWI560184B/zh not_active IP Right Cessation
- 2014-07-22 TR TR2018/19155T patent/TR201819155T4/tr unknown
- 2014-07-22 AP AP2016008989A patent/AP2016008989A0/xx unknown
- 2014-07-22 MA MA38801A patent/MA38801B1/fr unknown
- 2014-07-22 RS RS20190150A patent/RS58344B1/sr unknown
- 2014-07-22 AR ARP140102713A patent/AR097009A1/es active IP Right Grant
- 2014-07-22 DK DK14741648.1T patent/DK3024826T3/en active
- 2014-07-22 LT LTEP14741648.1T patent/LT3024826T/lt unknown
- 2014-07-22 RU RU2016106003A patent/RU2689305C2/ru active
- 2014-07-22 PT PT14741648T patent/PT3024826T/pt unknown
- 2014-07-22 SG SG11201600205XA patent/SG11201600205XA/en unknown
- 2014-07-22 CA CA2919572A patent/CA2919572C/en active Active
- 2014-07-22 PE PE2016000023A patent/PE20160241A1/es unknown
- 2014-07-22 SI SI201431038T patent/SI3024826T1/sl unknown
- 2014-07-22 MY MYPI2016700106A patent/MY193619A/en unknown
- 2014-07-22 US US14/905,985 patent/US9809574B2/en active Active
- 2014-07-22 PL PL14741648T patent/PL3024826T3/pl unknown
- 2014-07-22 GE GEAP201914063A patent/GEAP201914063A/en unknown
- 2014-07-22 UA UAA201601395A patent/UA117490C2/uk unknown
- 2014-07-22 HK HK16106761.6A patent/HK1218754A1/zh unknown
-
2016
- 2016-01-03 IL IL243449A patent/IL243449A0/en active IP Right Grant
- 2016-01-06 PH PH12016500034A patent/PH12016500034A1/en unknown
- 2016-01-11 ZA ZA2016/00198A patent/ZA201600198B/en unknown
- 2016-01-11 DO DO2016000009A patent/DOP2016000009A/es unknown
- 2016-01-15 CR CR20160030A patent/CR20160030A/es unknown
- 2016-01-20 CL CL2016000148A patent/CL2016000148A1/es unknown
- 2016-01-21 SA SA516370439A patent/SA516370439B1/ar unknown
- 2016-01-21 NI NI201600016A patent/NI201600016A/es unknown
-
2017
- 2017-09-14 US US15/704,330 patent/US10689364B2/en active Active
-
2019
- 2019-02-11 CY CY20191100175T patent/CY1121247T1/el unknown
-
2020
- 2020-05-04 US US16/865,799 patent/US11028070B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000009A (es) | Nuevos compuestos isoindolina o isoquinolina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| SV2017005587A (es) | Nuevos derivados hidroxiester, un proceso para su preparacion y composiciones farmaceutacas que los contienen | |
| SV2017005590A (es) | Nuevos derivados hidroxiacido un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| SV2017005589A (es) | Nuevos derivados biciclicos, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| SV2014004770A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y los composiciones farmacéuticas que los contienen | |
| SV2014004771A (es) | Nuevos derivados fosfatos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CU20140143A7 (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| SV2018005722A (es) | Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| NI201400081A (es) | Nuevos derivados de indolizina , su procedimiento de preparación y las composiciones farmacéuticas que los contienen. | |
| CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| UY35626A (es) | Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| UY35653A (es) | Nuevos derivados de indol y de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| SV2014004879A (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen |